Kiniksa Pharmaceuticals International, plc reported second-quarter 2026 results with revenue rising to $243.6M and diluted EPS of $0.3, driven by higher ARCALYST product sales and continued investment in R&D and commercial initiatives.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$243.6M$156.8M55.4% | Net income²$25.43M$17.83M42.6% | Diluted EPS³$0.3$0.2330.4% |
¹ Reported as “Total revenue”. ² Reported as “Net income”. ³ Reported as “income per share attributable to ordinary shareholders—diluted”.
Business Highlights
- Revenue growth was driven by ARCALYST product sales, which increased to $243.6M for the quarter and $457.9M year-to-date as more patients initiated therapy.
- ARCALYST continues to be distributed through a specialty pharmacy network and third‑party logistics; Samsung was approved as a replacement CDMO for drug substance.
- Kiniksa advanced its pipeline: KPL‑387 Phase 3 (PASTORALE) began enrollment in July 2026 with commercialization targeted for 2028–2029.
- Partnership activity included a $32M upfront/milestone payment from Huadong for China-region rights and a Genentech agreement retaining up to approximately $600M in contingent payments.
- The company increased R&D and commercial spending to support KPL programs and ARCALYST promotion, including DTC advertising and expanded headcount.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.